tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Keith Tapper, 10 are a BUY (100%).
Analyst Keith Tapper, currently employed at BARCLAYS, carries an average stock price target met ratio of 55.56% that have a potential upside of 66.21% achieved within 178 days.
Keith Tapper’s has documented 20 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NGNE, Neurogene at 20-Nov-2024.
Analyst best performing recommendations are on NGNE (NEUROGENE).
The best stock recommendation documented was for NGNE (NEUROGENE) at 10/16/2024. The price target of $65 was fulfilled within 19 days with a profit of $11.74 (22.04%) receiving and performance score of 11.6.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 28-Feb-2024
$35
$15.27 (77.39%)
$35
9 days ago
(19-Oct-2026)
9/16 (56.25%)
$15.2 (76.77%)
393
Buy Since 23-Jun-2025
$36
$16.27 (82.46%)
$37
20 days ago
(08-Oct-2026)
1/10 (10%)
$16.42 (83.86%)
173
Buy Since 15-Dec-2025
$33
$13.27 (67.26%)
$37
1 months 3 days ago
(25-Sep-2026)
0/3 (0%)
$12.32 (59.57%)
Buy Since 17-Apr-2025
$34
$14.27 (72.33%)
$36
1 months 3 days ago
(25-Sep-2026)
4/6 (66.67%)
$13.32 (64.41%)
144
Buy Since 25-Sep-2025
$31
$11.27 (57.12%)
$38
1 months 3 days ago
(25-Sep-2026)
1/4 (25%)
$10.32 (49.90%)
831
What Year was the first public recommendation made by Keith Tapper?
